GlassScriptPhysician profile
Felix Hernandez
NPI 1366734816
$9,274.24
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $619 · 2020: $373 · 2021: $69.37 · 2022: $4,568 · 2023: $837 · 2024: $2,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927 · Education: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.27 |
| Education | $717.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,899.27 | 2022-2024 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $934.88 | 2019-2024 | Fasenra, Airsupra, Tagrisso |
| Glaxosmithkline, LLC. | $882.13 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Actelion Pharmaceuticals US, INC. | $553.62 | 2019-2024 | Uptravi, Opsumit |
| Insmed, INC. | $261.00 | 2022-2024 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.02 | 2019-2024 | Spiriva Respimat, Ofev |
| Genzyme Corporation | $151.32 | 2024 | |
| Amgen INC. | $137.86 | 2023-2024 | Tezspire |
| Mylan Specialty L.P. | $132.34 | 2022-2024 | Yupelri |
| Pulmonx Corporation | $130.19 | 2021-2023 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Regeneron Healthcare Solutions, INC. | $125.81 | 2022-2024 | Dupixent |
| Mallinckrodt Enterprises LLC | $117.77 | 2019 | |
| Ani Pharmaceuticals, INC. | $91.04 | 2024 | Purified Cortrophin Gel |
| United Therapeutics Corporation | $85.14 | 2019-2024 | Tyvaso |
| Grifols USA, LLC | $82.60 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $63.55 | 2022 | |
| Merck Sharp & Dohme LLC | $58.89 | 2024 | Keytruda, Winrevair |
| Pfizer INC. | $55.94 | 2024 | |
| Edwards Lifesciences Corporation | $49.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.19 | 2024 | |
| Janssen Pharmaceuticals, INC | $36.35 | 2023-2024 | Xarelto |
| Mallinckrodt Hospital Products INC. | $31.37 | 2024 | Acthar |
| Genentech USA, INC. | $21.23 | 2024 | Venclexta |
| Inogen, INC. | $20.32 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Baxter Healthcare | $20.11 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Idorsia Pharmaceuticals US INC | $18.68 | 2024 | Quviviq |
| Shire North American Group INC | $15.61 | 2019 | |
| Circassia INC. | $14.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felix Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.